Login Register Cart 0
Meta-Analysis

化疗免疫治疗与化疗对胃癌的疗效:生存结果的荟萃分析

卷 31, 期 18, 2024

发表于: 23 January, 2024

页: [2649 - 2660] 页: 12

弟呕挨: 10.2174/0109298673263335231121103807

价格: $65

摘要

背景:传统上，化疗是胃癌的主要治疗方式。然而，最近的研究表明，化学免疫疗法也是有效的，在某些情况下，比化疗更好。本研究旨在探讨化疗免疫治疗与化疗治疗胃癌的疗效。 方法:利用PubMed、Embase、EBSCO等电子数据库，对2006 ~ 2023年的文献进行全面检索。搜索策略旨在识别基于化学免疫治疗和化疗干预的相关研究，并使用合适的关键词和MeSH术语进行搜索。检索到的研究根据标题、摘要和全文筛选相关性。预先定义了研究的纳入标准，然后使用GradePro GDT对选定的研究进行质量评估。使用Revman version 5.4对所选研究的数据进行提取和分析。 结果:研究发现，化疗免疫治疗导致总生存期(OS)显著改善，风险比(RR)为1.54,95%可信区间(CI)为1.25 ~ 1.89。总体效果也被发现是显著的，p值小于0.001。此外，我们还观察到1年、3年和5年生存率的改善，风险比(RR)分别为1.09 (95% CI: 1.01, 1.17)、1.43 (95% CI: 1.28, 1.60)和1.59 (95% CI: 1.10, 2.30)。此外，还发现化疗免疫治疗也改善了DFS, RR为1.94,95% CI为1.44 ~ 2.59。总的来说，这些结果表明，在研究人群中，与化疗相比，化疗免疫治疗可能是提高总生存率和无病生存率的有效方法。 结论:本研究比较了化疗免疫治疗与化疗治疗胃癌的疗效，发现两种治疗方法均有效，但化疗免疫治疗的疗效更显著。为了支持这些结果，需要更多的大样本研究和更长的随访时间。

关键词: 胃癌，化疗，免疫治疗，总生存率，无病生存率，树突状细胞。

« Previous
[1]
Wong, M.C.S.; Huang, J.; Chan, P.S.F.; Choi, P.; Lao, X.Q.; Chan, S.M.; Teoh, A.; Liang, P. Global incidence and mortality of gastric cancer, 1980-2018. JAMA Netw. Open, 2021, 4(7), e2118457.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.18457] [PMID: 34309666]
[2]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[3]
Dolcetti, R.; De Re, V.; Canzonieri, V. Immunotherapy for gastric cancer: Time for a personalized approach? Int. J. Mol. Sci., 2018, 19(6), 1602.
[http://dx.doi.org/10.3390/ijms19061602] [PMID: 29844297]
[4]
Takei, S.; Kawazoe, A.; Shitara, K. The new era of immunotherapy in gastric cancer. Cancers, 2022, 14(4), 1054.
[http://dx.doi.org/10.3390/cancers14041054] [PMID: 35205802]
[5]
Mu, W.; Chu, Q.; Liu, Y.; Zhang, N. A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nano-Micro Lett., 2020, 12(1), 142.
[http://dx.doi.org/10.1007/s40820-020-00482-6] [PMID: 34138136]
[6]
Salas-Benito, D.; Pérez-Gracia, J.L.; Ponz-Sarvisé, M.; Rodriguez-Ruiz, M.E.; Martínez-Forero, I.; Castañón, E.; López-Picazo, J.M.; Sanmamed, M.F.; Melero, I. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov., 2021, 11(6), 1353-1367.
[http://dx.doi.org/10.1158/2159-8290.CD-20-1312] [PMID: 33712487]
[7]
Jiang, H.; Wang, J.; Deng, W. Pathologic complete response to chemoimmunotherapy of an advanced gastric cancer patient with high PD-L1 expression, dMMR, and unique gut microbiota composition: A case report. Front. Oncol., 2023, 13, 1150931.
[http://dx.doi.org/10.3389/fonc.2023.1150931] [PMID: 37007083]
[8]
Garofano, F.; Gonzalez-Carmona, M.A.; Skowasch, D.; Schmidt-Wolf, R.; Abramian, A.; Hauser, S.; Strassburg, C.P.; Schmidt-Wolf, I.G.H. Clinical trials with combination of cytokine-induced killer cells and dendritic cells for cancer therapy. Int. J. Mol. Sci., 2019, 20(17), 4307.
[http://dx.doi.org/10.3390/ijms20174307] [PMID: 31484350]
[9]
Wang, S.; Wang, X.; Zhou, X.; Lyerly, H.K.; Morse, M.A.; Ren, J. DC-CIK as a widely applicable cancer immunotherapy. Expert Opin. Biol. Ther., 2020, 20(6), 601-607.
[http://dx.doi.org/10.1080/14712598.2020.1728250] [PMID: 32033522]
[10]
Murugan, D.; Murugesan, V.; Panchapakesan, B.; Rangasamy, L. Nanoparticle enhancement of Natural Killer (NK) cell-based immunotherapy. Cancers, 2022, 14(21), 5438.
[http://dx.doi.org/10.3390/cancers14215438] [PMID: 36358857]
[11]
Sharma, A.; Schmidt-Wolf, I.G.H. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J. Exp. Clin. Cancer Res., 2021, 40(1), 388.
[http://dx.doi.org/10.1186/s13046-021-02184-2] [PMID: 34886895]
[12]
Zhang, X.; Yang, J.; Zhang, G.; Lu, P.A. 11-Year clinical summary of DC - CIK / NK cell immunotherapy for 152 patients with acute myeloid leukemia. Blood, 2017, 130(Suppl. 1), 1369-69.
[http://dx.doi.org/10.1182/blood.V130.Suppl_1.1369.1369]
[13]
Joshi, S.S.; Badgwell, B.D. Current treatment and recent progress in gastric cancer. CA Cancer J. Clin., 2021, 71(3), 264-279.
[http://dx.doi.org/10.3322/caac.21657] [PMID: 33592120]
[14]
Esfahani, K.; Roudaia, L.; Buhlaiga, N.; Del Rincon, S.V.; Papneja, N.; Miller, W.H., Jr A review of cancer immunotherapy: from the past, to the present, to the future. Curr. Oncol., 2020, 27(12)(Suppl. 2), 87-97.
[http://dx.doi.org/10.3747/co.27.5223] [PMID: 32368178]
[15]
Xie, T.; Zhang, Z.; Zhang, X.; Qi, C.; Shen, L.; Peng, Z. Appropriate PD-L1 cutoff value for gastric cancer immunotherapy: A systematic review and meta-analysis. Front. Oncol., 2021, 11, 646355.
[http://dx.doi.org/10.3389/fonc.2021.646355] [PMID: 34540656]
[16]
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 2009, 6(7), e1000100.
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID: 19621070]
[17]
Schünemann, H.J.; Best, D.; Vist, G.; Oxman, A.D.; Group, G.W. Letters, numbers, symbols and words: How to communicate grades of evidence and recommendations. CMAJ, 2003, 169(7), 677-680.
[PMID: 14517128]
[18]
GRADEpro GDT. GRADEpro GDT: GRADEpro guideline development tool. McMaster University and Evidence Prime 2022. Available from: gradepro.org
[19]
Liu, G.; Chen, D.; Zhao, X.; You, X.; Huang, C.; Cheng, Z.; Mao, X.; Zhou, H. Efficacy of DC-CIK immunotherapy combined with chemotherapy on locally advanced gastric cancer. J. Oncol., 2022, 2022, 1-6.
[http://dx.doi.org/10.1155/2022/5473292] [PMID: 35865086]
[20]
Knödler, M.; Körfer, J.; Kunzmann, V.; Trojan, J.; Daum, S.; Schenk, M.; Kullmann, F.; Schroll, S.; Behringer, D.; Stahl, M.; Al-Batran, S.E.; Hacker, U.; Ibach, S.; Lindhofer, H.; Lordick, F. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br. J. Cancer, 2018, 119(3), 296-302.
[http://dx.doi.org/10.1038/s41416-018-0150-6] [PMID: 29988111]
[21]
Sahin, U.; Türeci, Ö.; Manikhas, G.; Lordick, F.; Rusyn, A.; Vynnychenko, I.; Dudov, A.; Bazin, I.; Bondarenko, I.; Melichar, B.; Dhaene, K.; Wiechen, K.; Huber, C.; Maurus, D.; Arozullah, A.; Park, J.W.; Schuler, M.; Al-Batran, S.E. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann. Oncol., 2021, 32(5), 609-619.
[http://dx.doi.org/10.1016/j.annonc.2021.02.005] [PMID: 33610734]
[22]
Malka, D.; François, E.; Penault-Llorca, F.; Castan, F.; Bouché, O.; Bennouna, J.; Ghiringhelli, F.; de la Fouchardière, C.; Borg, C.; Samalin, E.; Bachet, J.B.; Raoul, J.L.; Miglianico, L.; Bengrine-Lefèvre, L.; Dahan, L.; Lecaille, C.; Aparicio, T.; Stanbury, T.; Perrier, H.; Cayre, A.; Laurent-Puig, P.; Gourgou, S.; Emile, J.F.; Taïeb, J. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): A randomised, open-label, three-arm phase II trial. Eur. J. Cancer, 2019, 115, 97-106.
[http://dx.doi.org/10.1016/j.ejca.2019.04.020] [PMID: 31129386]
[23]
Liu, T.; Bai, Y.; Lin, X.; Li, W.; Wang, J.; Zhang, X.; Pan, H.; Bai, C.; Bai, L.; Cheng, Y.; Zhang, J.; Zhong, H.; Ba, Y.; Hu, W.; Xu, R.; Guo, W.; Qin, S.; Yang, N.; Lu, J.; Shitara, K.; Lei, M.; Li, M.; Bao, N.; Chen, T.; Shen, L. First- line nivolumab plus chemotherapy vs. chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CHECKMATE 649 Chinese subgroup analysis. Int. J. Cancer, 2023, 152(4), 749-760.
[http://dx.doi.org/10.1002/ijc.34296] [PMID: 36121651]
[24]
Li, Y.; Wang, C.; Xu, M.; Kong, C.; Qu, A.; Zhang, M.; Zheng, Z.; Zhang, G. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer. J. Cancer Res. Clin. Oncol., 2017, 143(5), 861-871.
[http://dx.doi.org/10.1007/s00432-016-2330-1] [PMID: 28108815]
[25]
Wang, Y.; Wang, C.; Xiao, H.; Niu, C.; Wu, H.; Jin, H.; Yao, C.; He, H.; Tian, H.; Han, F.; Li, D.; Han, W.; Xu, J.; Chen, J.; Cui, J.; Li, W. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer. Cancer Med., 2017, 6(1), 45-53.
[http://dx.doi.org/10.1002/cam4.942] [PMID: 27790867]
[26]
Zhou, C.; Wang, W.; Xie, J.; Zhang, Y.; Yang, Y.; Mu, Y. Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: A randomized Phase II study. OncoTargets Ther., 2016, 9, 4617-4627.
[http://dx.doi.org/10.2147/OTT.S107745] [PMID: 27524915]
[27]
Chen, Y.; Guo, Z.Q.; Shi, C.M.; Zhou, Z.F.; Ye, Y.B.; Chen, Q. Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. Int. J. Clin. Exp. Med., 2015, 8(5), 7728-7736.
[PMID: 26221323]
[28]
Gao, D.; Li, C.; Xie, X.; Zhao, P.; Wei, X.; Sun, W.; Liu, H.C.; Alexandrou, A.T.; Jones, J.; Zhao, R.; Li, J.J. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One, 2014, 9(4), e93886.
[http://dx.doi.org/10.1371/journal.pone.0093886] [PMID: 24699863]
[29]
Liu, H.; Song, J.; Yang, Z.; Zhang, X. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp. Ther. Med., 2013, 6(4), 953-956.
[http://dx.doi.org/10.3892/etm.2013.1247] [PMID: 24137296]
[30]
Zhao, H.; Fan, Y.; Li, H.; Yu, J.; Liu, L.; Cao, S.; Ren, B.; Yan, F.; Ren, X. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: A retrospective study of 165 patients. Cancer Biother. Radiopharm., 2013, 28(4), 303-309.
[http://dx.doi.org/10.1089/cbr.2012.1306] [PMID: 23506427]
[31]
Shi, L.; Zhou, Q.; Wu, J.; Ji, M.; Li, G.; Jiang, J.; Wu, C. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol. Immunother., 2012, 61(12), 2251-2259.
[http://dx.doi.org/10.1007/s00262-012-1289-2] [PMID: 22674056]
[32]
Jiang, J.T.; Shen, Y.P.; Wu, C.P.; Zhu, Y.B.; Wei, W.X.; Chen, L.J.; Zheng, X.; Sun, J.; Lu, B.F.; Zhang, X.G. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J. Gastroenterol., 2010, 16(48), 6155-6162.
[http://dx.doi.org/10.3748/wjg.v16.i48.6155] [PMID: 21182234]
[33]
Jiang, J.; Xu, N.; Wu, C.; Deng, H.; Lu, M.; Li, M.; Xu, B.; Wu, J.; Wang, R.; Xu, J.; Nilsson-Ehle, P. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res., 2006, 26(3B), 2237-2242.
[PMID: 16821594]
[34]
Sumer, F.; Gundogan, E.; Kaplan, K.; Okut, G.; Kayaalp, C. Transvaginal specimen extraction after laparoscopic gastrectomy for tumors. Surg. Laparosc. Endosc. Percutan. Tech., 2022, 32(2), 247-251.
[http://dx.doi.org/10.1097/SLE.0000000000001031] [PMID: 34966150]
[35]
Hashimoto, I.; Oshima, T. Claudins and gastric cancer: An overview. Cancers, 2022, 14(2), 290.
[http://dx.doi.org/10.3390/cancers14020290] [PMID: 35053454]
[36]
Lee, J.L.; Kang, Y.K. Capecitabine in the treatment of advanced gastric cancer. Future Oncol., 2008, 4(2), 179-198.
[http://dx.doi.org/10.2217/14796694.4.2.179] [PMID: 18407732]
[37]
Huynh, J.; Patel, K.; Gong, J.; Cho, M.; Malla, M.; Parikh, A.; Klempner, S. Immunotherapy in gastroesophageal cancers: Current evidence and ongoing trials. Curr. Treat. Options Oncol., 2021, 22(11), 100.
[http://dx.doi.org/10.1007/s11864-021-00893-6] [PMID: 34524553]
[38]
Högner, A.; Moehler, M. Immunotherapy in gastric cancer. Curr. Oncol., 2022, 29(3), 1559-1574.
[http://dx.doi.org/10.3390/curroncol29030131] [PMID: 35323331]
[39]
Zhang, L.; Mu, Y.; Zhang, A.; Xie, J.; Chen, S.; Xu, F.; Wang, W.; Zhang, Y.; Ren, S.; Zhou, C. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients. Oncotarget, 2017, 8(28), 45164-45177.
[http://dx.doi.org/10.18632/oncotarget.16665] [PMID: 28404886]

Rights & Permissions Print Cite
Article Metrics
23
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy